Sodium valproate use in women and girls of childbearing years

Experts from 13 national bodies, including seven Royal Colleges, joined forces in March 2019 to launch practical guidance to support doctors and other health professionals around the use of this medicine in women and girls in their reproductive years.

In recent years the ongoing concern about use of sodium valproate in females who might become pregnant has resulted in changes to the licensed indication, such that sodium valproate is contraindicated in women and girls of childbearing potential unless the conditions of a Pregnancy Prevention Programme (PREVENT) are met.

This joint guidance from RCPCH and British Paediatric Neurology Association (BPNA) aims to clarify the approach to prescribing valproate in female patients under 18 years Download Prescribing valproate to female patients under 18 years of age below.